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Abstract
Notch 1 is an evolutionarily conserved cell signaling receptor with important functions ranging
from control of stem cell proliferation and differentiation to regulation of angiogenesis.
Accordingly, Notch 1 expression affects a diverse assortment of protein targets. Here, we explore
the role that Notch 1 and related signaling molecules play in astrocyte cell biology. Specifically,
we investigate exosomes and the transduction of Notch signaling in astrocytes. Exosomes are
small (10-150 nm) vesicles secreted by most cell types and have been found to contain cargo
ranging from small RNA species to full length transmembrane receptors. We report, for the first
time to our knowledge, the identification of the Notch 1 intracellular domain (NICD), the
signaling-competent portion of the Notch 1 receptor, within exosomes secreted from astrocytes.
Although NICD was detectable in astrocyte exosome samples, we were unable to demonstrate that
exosomal NICD was biologically active or signaling-competent in assays measuring Notch target
gene expression or neural stem cell proliferation. We also performed experiments interrogating the
function of Glypican 4 (a Notch-regulated heperan sulfate proteoglycan) in astrocytes, given our
identification of Glypican 4 expression as regulated by Notch 1 by microarray. While Glypican 4
is known to exist in a GPI-tethered and in a secreted form, we detected significant nuclear
Glypican 4 expression in astrocytes. Given the nuclear localization and highly punctate nature of
Glypican 4 expression in astrocytes, we hypothesized potential involvement in alternative splicing.
Nuclear Glypican 4 was found to colocalize with RbFox3/NeuN, a known effector of alternative
splicing. Taken together, these experiments underscore the importance of Notch signaling to
astrocyte cell biology and provide a basis for further experiments interrogating the mechanistic
details underlying these findings.
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Introduction
Cell to cell communication is an integral part of biological systems, and cells employ a wide variety of
mechanisms to communicate. This is particularly true in the central nervous system (CNS), where specialized
mechanisms allow for the exchange of information in high resolution, complex networks. In addition to
neuronal electrical activity, an array of other communication mechanisms are employed by both neuronal
and glial cells, such as the secretion of vesicles into the extracellular space. Exosomes are a specific type of
extracellular vesicle (EV) that are secreted by many, if not all, cells within the CNS1-5 and other somatic
tissues. Exosomes can be distinguished from other EVs by their size, density, enrichment in certain proteins,
and their biogenesis. Exosomes carry a wide variety of cargo ranging from miRNA species to full length
transmembrane receptors, suggesting their potential role as mediators of cell signaling 3, 6-9. As exosomes are,
at least in part, a representation of their parent cell they have also garnered interest in the medical community,
both as biomarkers of and as mechanistic components of CNS pathology.
While exciting progress has been made in recent years in the exosome field, a lack of methodological
standardization has hampered progress to an appreciable degree. This problem is further compounded by the
increasingly apparent heterogeneity of exosomes, as well as the technical challenges of isolating and working
with them. A wide variety of techniques are currently being used to isolate or purify exosomes, including
ultracentrifugation, immunocapture, ultrafiltration, and commercially available kits that use a density or
precipitation-based approach.
Published studies have highlighted the impact that isolation strategy and cell culture methods can
have on a given exosome sample, raising concerns about experimental reproducibility10-12. While new
approaches and methodologies are of great value to the field of exosome research, the current lack of
consensus regarding tools and methods may further hamper progress. This is especially true with respect to
clinical applications of exosomes as biomarkers of disease or even as potential therapeutic vectors.
Standardization of methodology is required, particularly in instances where patients are concerned.
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The Exosome
Exosomes, while similar to other types of EVs, are distinct in several key characteristics. They are often
distinguished by their size (~10-150 nm) and their enrichment in specific tetraspanin proteins13, 14. The
tetraspanins are a family of 4-pass transmembrane proteins that control membrane fusion and cell adhesion,
amongst other functions. Tetraspanins are highly enriched in exosomal membranes and are useful for positive
identification or antigen-specific isolation of exosomes in combination with other purification techniques.
Tetraspanins also form convoluted networks of protein-protein interactions on the exosomal (and cell)
surface, in structures referred to as tetraspanin webs or tetraspanin-enriched microdomains (TEMs) 15.
The biogenesis of exosomes is distinct from that of other EVs. Exosomes are generated from the
endosomal pathway and originate as intraluminal vesicles (ILVs) within a multivesicular body (MVB).
MVBs are targeted to the lysosome for degradation or release their cargo into the extracellular space (as
exosomes) after fusion with the plasma membrane (Figure i.). The formation of the MVB and its constituent
ILVs is believed to require the activity of the ESCRT family of proteins. There are 4 individual proteins
(ESCRT 0-3) that participate in exosome biogenesis as well as other functions related to the endosome (See
Henne, Buchkovich, and Emr, 2011. for review16). Briefly, this mechanism relies on ESCRT-0 to sequester
ubiquitinated cargo to the endosomal membrane, after which fusion with the other 3 ESCRT proteins
promotes abscission and budding of ILVs within the MVB membrane17-19.
In part, this system provides a mechanism for discriminative cargo selection; cargo is selected by
ESCRT-0 by recognition of a ubiquitin tag and subsequently engaged by the other ESCRT proteins to be
incorporated into the exosome. Importantly, the mechanism by which the endosomal pathway and ESCRT
proteins discriminate between the lysosome and the exosome is still not well understood. One proposed
mechanism involves ISGylation, a process where a ubiquitin-like tag appended to MVB proteins induces
lysosomal degradation30. It is possible that the balance of secretion and degradation is fine-tuned by the
tagging of MVB or ILV proteins in this manner.
A secondary, ESCRT protein-independent mechanism has been proposed for incorporation of
specific exosomal cargo. In this hypothesis, lipid species and tetraspanin webs cooperatively form
microdomains within endosomal membranes to laterally segregate cargo destined for an exosome. 15 The
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specific responsibility of tetraspanin proteins in directing exosomal cargo is highlighted in this system.
Tetraspanin webs may, by virtue of their protein-protein interactions, recruit and sequester cargo into such
microdomains and then into exosomes. Supporting this hypothesis is the observation that deletion of CD81,
an exosome-associated tetraspanin, prevents the interaction of exosomes with CD81 binding partners20.
While these two mechanisms together represent a system by which cargo can be sorted into the exosome, we
still understand very little about the broader context in which this system operates. A complete understanding
of how cargo is directed to the exosome would be of great value and could potentially shed light on some of
the biological functions of exosomes.
The Exosome: Trash Disposal or Paracrine Signal?
A pervasive question within the exosome field is to what extent exosomes act as mediators of cell signaling.
They certainly contain signaling-competent cargo, having been described as containing a variety of RNA
species, proteins, and lipids within and inside their membranes. Furthermore, at least two independent
mechanisms by which cargo can be specifically directed to the exosome have been described. Importantly,
however, the same mechanisms responsible for exosome biogenesis are also capable of targeting contents to
the lysosome for degradation. When secreted, exosomes may provide a mechanism to remove intracellular
waste products to the extracellular space. Indeed, one of the early hypotheses that arose immediately
following the discovery of exosomes was that they functioned to remove unneeded proteins or other cellular
waste in maturing or differentiated cells21. More contemporary hypotheses propose that exosomes represent
an alternative mechanism for waste removal or homeostatic maintenance. In support of this theory, it was
demonstrated that inhibiting exosome secretion causes a buildup of nuclear DNA within the cytoplasm that
results in reactive oxygen species-dependent damage and apoptosis22. This mechanism appeared to be more
prevalent in senescent cells that may be more vulnerable to homeostatic disturbance or, alternatively, may
themselves have altered exosomal secretion.
Within the CNS specifically, the waste removal hypothesis is supported by several observations that
toxic protein aggregates characteristic of neurodegenerative diseases like Alzheimer’s Disease and
Parkinson’s Disease, are secreted exosomally23, 24. In many cases, these aggregates are resistant or impervious
to normal lysosomal degradation, and as such exosomal secretion represents a potentially attractive
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alternative means of disposal from the cell. Some studies, however, have indicated that aggregates secreted
in this manner may be capable of seeding aggregation in otherwise naïve cells25; an obviously dangerous and
undesirable consequence that may in fact be a pathogenic process in and of itself. Knowledge of the
mechanistic details of such a regulatory system would be of great value to both our understanding of cell
biology and to the treatment of disease.
While initial hypotheses concerning the function of exosomes posited them as a waste disposal
mechanism or as homeostatic regulators, an increasing body evidence suggests that exosomes play an active
role in cell signaling. Most basically, regulated release of exosomes has been demonstrated; this a
fundamental aspect of directed cell signaling26. Also, activation of downstream signaling pathways by
exosomal cargo in recipient cells has been shown to occur in several instances 27-29. In one case, Transforming
Growth Factor Beta 1 (TGF-ß1) within mast cell exosomes was shown to induce TGF signaling and
downstream Small Worm/Mothers Against Decapentaplegic (SMAD) activation, as well as increased cell
motility and migration, in recipient cells27. In another, a mutant form of ß-catenin contained within exosomes
secreted from colorectal cancer cells was demonstrated to activate its cognate Wingless/Int-1 (Wnt) signaling
pathway in recipient cells, implying a role for exosomes in both cell signaling and disease pathogenesis 28.
Translation of exosomal RNA cargo was demonstrated in recipient cells in a cell-type specific manner 6, thus
providing a mechanism for exosomes to affect protein expression and behavior in the target cell. While it is
likely that cells utilize exosomes for both waste management and directed signaling, the extent to which each
of these two processes are utilized and how cells distinguish between these two pathways is not well
understood.
Neuronal Cells and Exosomes
Neurons both secrete and take up exosomes. A study in the early 2000s demonstrated that cultured cortical
neurons release exosomes after cell depolarization3. The observation of depolarization-induced release of
exosomes agreed with an earlier observation in an immortalized cell line, that exosome release is calciumdependent26. The observation was confirmed in neuronal cells five years later, by utilizing calcium chelators
and ionophores to block and potentiate neuronal exosome release, respectively 1. This study also demonstrated
that exosome release was induced specifically by glutamatergic activity, and that exosomes released in close
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proximity to the postsynaptic membrane contained the GluR2/3 AMPA receptor subunit. These findings raise
interesting questions concerning the purpose of activity-regulated exosomes. Is the exosomal release of
GluR2/3 a homeostatic mechanism to fine-tune the postsynaptic response to glutamate, or to discard old or
otherwise unneeded receptors?
Subsequent work by Sadoul et al., however, casts some doubt on this hypothesis. They observed
that while exosomes secreted by an immortalized neuroblastoma cell line were taken up fairly
indiscriminately by co-cultured neurons and glial cells, the exosomes released by cultured cortical neurons
upon stimulation were taken up only by neurons31. What distinguished these two populations of seemingly
similar exosomes was not explored in this specific study, but others have identified tetraspanins and integrins
as crucial regulators of target cell selectivity in exosomes14. Of note, it is possible that exosomes secreted by
neurons express a particular combination of tetraspanins and integrins that precludes promiscuous dispersal
of their contents. Although it was not specifically demonstrated that the exosomes in this study themselves
contained the GluR2/3 subunit, the specificity of target selection seems to imply exosome functions beyond
the simple removal of aged receptors.
While the previously described study observed neuronal exosomes interacting with neurons,
instances of neuronal exosomes affecting glial cells have also been reported. In one particularly interesting
study by Yang et al., neuronal exosomes were found to increase astrocyte GLT1 protein expression 31. GLT1
is an important glutamate reuptake transporter expressed by astrocytes and is crucial for maintaining proper
synaptic physiology. It was demonstrated that exosomes harvested from neurons increase GLT1 protein
expression in primary astrocytes, without affecting mRNA levels. This affect was abrogated by an miRNA
124a antisense oligonucleotide, suggesting the effects were mediated by this specific miRNA. Injection of
antisense oligos was shown to alter glutamatergic dynamics ex vivo in brain slice recordings and to reduce
GLT1 protein levels when injected directly into mouse striatal tissue, implicating this exosomal miRNA in
the regulation of synaptic physiology.
There were key differences between these two studies, both in design and in methodology, that may
help explain the disparity in results. The exosomes harvested in the Sadoul et al. study were harvested
following glutamatergic synaptic activity whereas the Yang study harvested exosomes secreted
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constitutively. Furthermore, Yang et al. reported no evidence of exosome release in response to synaptic
activity. Importantly, there are also key methodological differences between the studies that may have
contributed to the differing results. Both studies utilized cortical neurons, but they were isolated and cultured
under different conditions. Both studies harvested exosomes by ultracentrifugation but used fundamentally
different approaches. Exosome treatment times also differed. Comparing results is difficult, if not impossible,
when fundamental methodological details are at odds; this further underscores the need for methodological
standardization within the exosome field.
Direct regulation of electrophysiological activity or neuronal protein expression is not the only
manner in which exosomes may exert control over neuronal signaling. Neuronal networks are complex, and
cellular mechanics that alter neuronal network activity are numerous and varied in nature. Pruning of
synapses is one mechanism whereby network activity can be fine-tuned and is largely accomplished by
microglia. Microglial cells are the brain resident macrophages and are largely known to be responsible for
phagocytosis and immune defense within the nervous system. Some mechanisms whereby neurons can signal
to microglia to direct synapse pruning have been described, but the process is far from fully understood.
Supporting the involvement of exosomes, Bahrini et al. (2015) demonstrated that neuronal exosomes enhance
the ability of microglia to prune synapses in an ex vivo assay. This was accomplished by an upregulation of
complement factors in the microglia by neuronal exosomes33. Given that no mRNA for complement proteins
could be detected in isolated neuronal exosomes, the authors speculated that the effect was likely indirect,
and possibly mediated through miRNAs as previously described for the regulation of GLT1.
Glial Exosomes
Given the myriad roles that glial cells play within the CNS, both in support of and as active participants in
signaling networks, it is perhaps no surprise that glial exosomes also have signaling functions. Astrocytes are
uniquely positioned to regulate neuronal activity and much contemporary glial cell research is dedicated to
determining the precise nature of astroglial communication mechanisms, both with neurons and with other
glial cells. Of particular interest is how astrocytes may mediate neuronal electrophysiological behavior. In
one study, exosomes harvested from primary human astrocytes were shown to influence both neurite
extension and spike dynamics when applied to neuronal cell cultures5.
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Neuron-derived exosomes containing miRNA were shown to regulate astrocyte protein
expression31. However, astrocytic miRNAs are also implicated in exosomal biology. Notably, profiling of
miRNA expression in primary astrocytes vs. astrocyte-secreted exosomes revealed significant differences in
miRNA content34. Indeed, this study described 12 miRNAs as present only in astrocyte exosomes, but not in
astrocytes. This observation suggests a sorting mechanism whereby miRNAs are specifically shunted to the
exosome. The authors did not investigate the specific function of any of the putative exosome-specific or
exosome-enriched miRNAs, although they did cite other studies that described functions of the miRNAs in
regulation of neural progenitor cell proliferation and differentiation.
It has been demonstrated that microglia also secrete exosomes and, in one case, did so in response
to serotonergic neuronal singaling32. Again, in agreement with previous studies, this mechanism was shown
to be calcium-dependent. This effect was mediated by microglial 5-HT2 receptors coupled to PLC signaling,
the activation of which led to an increase in intracellular calcium and stimulated exosome release. This affect
was demonstrated most conclusively when BV-2 cells, an immortalized microglial cell line, were co-cultured
with serotonergic neurons derived from embryonic stem cells. The BV-2 microglia in co-culture secreted
significantly more exosomes than when these cells were cultured without neurons, an effect that was blocked
by inclusion of serotonin receptor antagonists. The contents of the microglial exosomes was not determined
in this study, although the authors speculated that since microglia are already known to secrete a variety of
growth factors beneficial to neurons, the exosomes may serve a similar supportive or homeostatic role.
In a similar study, it was shown that Wnt3a induces exosome secretion from primary rat microglial
cells35. While little to no exosome secretion was observed from control cells, Wnt3a-treated microglia
secreted a significant amount of exosomes into their culture medium. This observation was in contrast to the
behavior of primary cortical neuronal cells, which were observed in this case to secrete exosomes
constitutively and did not respond to Wnt3a treatment. Furthermore, the effect was specific to Wnt3a, as
Wnt5a and Wnt5b were unable to prompt microglial exosome secretion35. These observations provide an
interesting point of comparison to the findings of the previously described study in which serotonin prompted
microglial exosome release. In both cases, microglial exosome secretion was observed to be largely
dependent on an input stimulus rather than occurring constitutively. In one study, the stimulus came in the
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form of a cell-surface receptor, whereas in the latter case the stimulating ligand (Wnt3a) was internalized and
acted intracellularly. Interestingly, exosome secretion in response to Wnt3a was observed to be GSK3ßindependent, unusual for canonical Wnt signaling, which is typically GSK3ß-dependent.
In a different study, exosomes secreted by an oligodendrocyte precursor cell line were labeled with
fluorescent dye and then fed to primary cultures of oligodendrocytes, neurons, astrocytes, or microglia.
Selective uptake of the labeled exosomes by microglia was observed, an effect that was replicated in primary
mixed glial co-cultures and also with exosomes harvested from primary rat oligodendrocytes36. Another study
examined the relationship between microglia and neural stem cell (NSC) exosomes. Here, it was observed
that NSCs in the neonatal subventricular zone (SVZ) released exosomes that were preferentially taken up by
microglia37. Results from analysis of cell morphology and RNA sequencing (small RNA-seq) demonstrated
that these exosomes induced both morphological and transcriptional changes in recipient microglia,
ultimately affecting microglial cytokine release and NSC proliferation in a feedback loop. Although this
study made use of a non-specific electroporation-based approach for EV tracking, their results were
interesting and provided important insight into the putative functional consequences of microglial exosome
uptake.
Exosomes in CNS Disease and Pathology:
Whereas exosomes appear to play myriad roles in the maintenance of normal CNS functions, they also likely
function in the context of CNS diseases and disorders. Given that exosomes provide at least a partial
representation of their cells of origin, much attention has been given to the possibility that exosomes could
serve as disease biomarkers to aid in detection and diagnosis. Given the widespread interest and subsequently
large body of literature relevant to this topic it would be difficult to provide a comprehensive overview of
exosomal biomarker research. Accordingly, a few examples relevant to CNS pathology will be discussed
herein.
One advantage of using exosomes as disease biomarkers is that exosomes appear to be widely
distributed throughout the body, regardless of their origin. Taking advantage of this property, one study used
exosomes isolated from peripheral blood plasma to distinguish between cases of ischemic and hemorrhagic
stroke, with a high degree of accuracy38. While stroke-related pathology and the time-intensive nature of
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exosome isolation limit the practical utility of this specific observation in terms of diagnosis, the study
provided insight into the potential for exosomal cargo to relay information about ongoing disease processes.
It also highlighted the accessibility of exosomes of putative CNS origin (the cells of origin were not
conclusively identified in this study), an important consideration given the invasive nature of directly
obtaining CNS tissue (by biopsy, etc.).
Chronic neurodegenerative diseases are attractive targets for exosome biomarker research. In light
of present difficulties in early detection and diagnosis of these diseases having easily accessible biomarkers
could greatly aid in both diagnosis and disease management. Investigating the distribution of CNS-derived
α-synuclein, the protein hallmark of Parkinson’s Disease, one study injected labelled α-synuclein into the
mouse brain. Notably, a subset of the protein was recruited into exosomes which were detectable in
peripherally-isolated blood plasma23. When exosomes were isolated from plasma samples of Parkinson’s
Disease patients, it was observed that levels of α-synuclein were significantly higher as compared to healthy
controls. This is in contrast to levels of cerebrospinal fluid (CSF) α-synuclein, which have previously been
reported to be lower in Parkinson’s patients as compared with controls39. Finally, a significant correlation
between plasma exosomal α-synuclein and disease severity was observed, underscoring the potential utility
of exosomes as biomarkers for Parkinson’s Disease.
Exosomes have also been investigated in the context of Alzheimer’s Disease (AD), another
prevalent neurodegenerative disease. It was demonstrated that astrocyte exosomes, isolated from the
peripheral blood plasma of AD patients, were significantly enriched in complement and inflammatory factors
such as complement 1q, complement 4b, Interleukin-6, and Tumor Necrosis Factor-α 40. While these factors
are not necessarily specific to AD pathology in the same manner as α-synuclein, it was observed that mean
complement levels correlated significantly with disease stage and were higher in AD2-moderate dementia
patients than in AD1-preclinical patients. This study provides proof of principal for the concept of
peripherally-isolated exosomes as biomarkers of CNS pathology, as the exosomes were isolated from
peripheral plasma using a largely astrocyte-specific approach. Whether these specific inflammatory factors
are relevant to disease pathogenesis or simply a reflection of the CNS response to the disease process, still
remains to be seen.
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While our understanding of the potential of exosomes as CNS biomarkers is still improving, it is
clear that exosomes can act as functional effectors of cell signaling and contribute to signaling events in CNS
disease states. Thus, exosomes act within the context of CNS pathology, not only as biomarkers but also as
active participants in the disease process. Given the wide variety of potential exosomal cargo and the many
distinct mechanisms by which a disease state may alter exosomal dynamics, exosomal signaling in disease
may be both beneficial and deleterious, depending on the underlying signaling environment.
Exosomal involvement in the inflammatory response, and the cell signaling underlying it, has been
the subject of much research. Many CNS pathologies involve some degree of inflammatory signaling, either
as a key pathophysiological feature or as a byproduct of injury. While our understanding of the factors that
regulate or induce inflammation is fairly robust, the involvement of exosomes in modulating or responding
to inflammation has the potential to alter the current model of inflammatory signaling.
Inflammatory signaling in the CNS is complex and may involve reciprocal communication between
multiple cell types. In one series of experiments, astrocyte-derived exosomes were shown to have differential
effects on neuronal cells when donor cells were exposed to Tumor Necrosis Factor α and Interleukin 1-ß 41.
Exosomes harvested from astrocytes exposed to these cytokines had altered microRNA profiles, that altered
neuronal morphology and growth when exosomes were applied to neuronal cells. These exosomes contained
microRNAs that were shown to downregulate neurotrophin signaling in recipient neurons. This
downregulation resulted in reduced dendritic complexity and electrophysiological activity (activity-relevant
effects were specific to IL-1ß). Given the ubiquitous expression of these two cytokines and their documented
involvement in a variety of neuroinflammatory conditions, further investigation into the extent to which
neuronal activity and survival is dependent on exosomal signaling should be conducted.
One specific CNS pathology in which inflammation, and specifically reactive astrocyte-mediated
inflammation, plays a major role is spinal cord injury (SCI). SCI is debilitating and unfortunately lacks an
effective treatment strategy. This is due, at least in part, to the glial scar, an aggregation of reactive astrocytes
that form around the initial lesion; glial scarring was historically believed to inhibit axon regeneration. In one
study, neuronal exosomes were shown to modulate glial scar formation in a model of SCI42. It was observed
that exosomes secreted by neurons treated with an agonist to RARß (retinoic acid receptor ß) were taken up
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by astrocytes, resulting in decreased proliferation and a reduction in the formation of a glial scar.42 It was
further observed that peripheral treatment of SCI rats with the same RARß agonist resulted in increased
axonal regeneration with subsequent functional motor recovery. Although treatment with exosomes alone
was not sufficient to induce axon regeneration or functional recovery, modulation of the glial scar
environment will likely factor into any successful treatment paradigm for SCI. Furthermore, these studies
provide evidence that exosomal communication is sufficient to induce significant phenotypic changes in CNS
cells, with important physiological consequences.
While the glial scar plays an inarguably important role in the pathophysiology of and recovery from
SCI, plasticity of neuronal cell axons and their ability or inability to regenerate after damage is the single
most important functional determinant of lasting disability in cases of SCI. During development, many of the
instructive cues which permit the growth of and guide growing axons are themselves paracrine factors,
suggesting a potential role for exosomes in this behavior.
One study reported that treatment with fibroblast exosomes permitted significant neurite outgrowth
from neuronal cells grown on myelin, which is known to be inhibitory to axon growth 43. Subsequent
mechanistic experiments found that Wnt10b regulated neurite and axon growth on inhibitory substrates, as
evidenced by gene knockout and neutralizing antibody experiments43. To demonstrate the in vivo relevance
of these effects, a model was employed wherein rats were subjected to an optic nerve crush injury with
concomitant intravitreal delivery of exosomes or vehicle. Exosome injection resulted in significantly
increased axon regeneration as compared to the PBS control. They also showed that fibroblast exosomes, via
modulation of Wnt and downstream mTOR signaling, have the potential to improve outcomes after a nerve
injury in the adult (rodent) CNS.
Notch Signaling and Exosomes
It is clear that a wide variety of cell signaling pathways are to some extent involved in exosomal
communication. While many cell signaling pathways have been investigated with respect to their
involvement in exosomal communication, others have received less attention. One such pathway is that of
Notch receptor signaling which has been minimally studied in the exosomal context. Notch receptor signaling
is an ancient and evolutionarily conserved signaling pathway that plays critically important roles in a variety
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of contexts. Notch receptor signaling is significant not only in its ubiquitous nature, but also in the unique
mechanism by which it takes place. The Notch family of receptors consists of 4 member genes that encode
Notch receptors 1-4. The work in this thesis is focused specifically on Notch 1.
Notch 1 is a single pass transmembrane receptor44, which like all cell signaling receptors requires
the binding of a ligand for its activity. A large family of Notch ligands has been described, some of which
are agonistic and some of which are antagonistic to downstream effectors of Notch signaling. Similar to cell
surface receptors, most Notch ligands are single-pass transmembrane proteins45. This feature, common to
both the Notch 1 receptor and its ligands, necessitates cell-cell contact and mechanical tension for signaling
initiation and plays an integral role in Notch signaling and its cellular consequences.
Notch signaling is initiated when a Notch ligand on one cell interacts with the Notch 1 receptor on
an adjacent cell. Ligand binding initiates a conformational change in the Notch 1 receptor, exposing cleavage
sites and prompting two proteolytic cleavages within the receptor. The second cleavage, carried out by γsecretase, frees the Notch intracellular domain (NICD) from the membrane-bound portion of the receptor4446

. Once cleaved, NICD is free to translocate into the nucleus where it forms a complex with other proteins

(most significantly the DNA binding protein CSL) to regulate transcription of associated genes. Importantly
this complexation displaces from CSL constitutively bound elements that, in the absence of Notch signaling,
repress Notch target genes. This results in the recruitment of transcription co-activators rather than repressors,
thereby activating Notch target gene expression47.
Notch signaling is critical for proper lateral inhibition during CNS development. The model of
lateral inhibition describes the process by which a cluster of neural progenitor cells make Notch 1-mediated
fate decisions during development. Initially, all neural progenitors in a given cluster of cells will express
similar levels of proneural genes and Delta-like 1 (Dll1, an inhibitory Notch ligand). Dll1 on one cell binds
with Notch 1 on adjacent cells and represses proneural gene expression. Over time, due to small variations
in receptor and ligand expression, Notch signaling (and thus proneural gene expression) will be more potently
inhibited in some cells compared with others. The cells which are less inhibited by proximate Dll1 expression
express proneural genes and differentiate into neuronal cells, while inhibited cells remain in their progenitor
state48. In this manner, Notch receptor signaling exerts control over neuronal differentiation in the CNS. The
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phenomenon of reciprocal lateral inhibition highlights both the importance of Notch signaling to the CNS,
as well as the importance of cell-cell contact in the context of Notch signaling.
Given the importance of precise cellular organization and patterning within the CNS, tight control
over Notch signaling is essential for proper development. Homozygous mutant mice lacking Notch 1 die at
or around embryonic day 11.5, a timepoint corresponding to early neuronal differentiation/maturation49.
Subsequent studies have more discretely examined the mechanisms underlying the effects of Notch signaling
on CNS cells. The Hes and Hey family of genes are key targets of Notch signaling and are known to be
important regulators of stem cell biology within the CNS. Mice lacking key Hes and Hey member genes were
found to undergo precocious neurogenesis, a correspondent lack of late-born neuronal cells, and grossly
disorganized CNS morphology50.
Whereas Notch is necessary for the maintenance of NSCs, it does not appear that Notch elements
are necessary for their initial generation51, 52 . In addition to acting as an inhibitor to premature differentiation,
Notch promotes or induces differentiation, specifically into glial cell lineages. In one study, cultured
multipotent hippocampal progenitors were induced to specifically differentiate into astrocytes through forced
expression of Notch 1 and 353. Furthermore, viral introduction of activated Notch 1 (NICD) into the mouse
forebrain, was able to induce differentiation of infected cells into radial glia at E9 52.
Our current understanding of the mechanics of Notch signaling is predicated on the idea that Notch
signaling requires cell-cell contact for initiation. Since a portion of the Notch receptor is cleaved
proteolytically it was assumed to remain inside the cell and be degraded or recycled. However, this
assumption has been challenged by the recent discovery of Notch-related proteins located on or within
secreted exosomes. The potential for a paracrine mechanism to activate Notch receptors is relevant to many
fields of study within neuroscience and developmental biology.
Delta-like 4 (Dll4) is a Notch ligand which regulates proliferation and differentiation of endothelial
cells in the context of angiogenesis. One study has identified Dll4 within exosomes secreted by cultured
human umbilical vein endothelial cells (HUVECs). Furthermore, the treated cells downregulated Notch target
genes, indicating successful reduction in Notch signaling by exosomal Dll454. Exosomal Dll4 was also shown
to increase vessel branching and density in an in vitro angiogenesis model, as well as in an ex vivo tumor
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xenograft model (vessel length and size were also increased in the xenograft experiments54). Finally, it was
shown through cell surface biotinylation experiments that exosomal Dll4 inhibits Notch signaling by binding
to the receptor, targeting the receptor for internalization and degradation, reducing cell-surface expression of
the Notch 1 receptor and in this manner abrogating Notch signaling and downstream target gene expression.
Another study demonstrated the presence of Jagged 1, an agonist-like Notch ligand, in exosomes
secreted by mesenchymal stem cells (MSCs)55. It was observed that the packaging of Jagged 1 into exosomes
was potentiated by overexpression of Hypoxia Inducible Factor-1α, a well-known regulator of
angiogenesis56. Exosomal Jagged 1 was shown to be active in recipient endothelial cells, and exosome
treatment significantly increases Hes and Hey family member gene expression. Furthermore, assays of
capillary tube formation using cultured HUVECs demonstrated that exosomal Jagged 1 can induce
angiogenesis, a phenomenon confirmed in vivo by a Matrigel plug growth assay55.
Taken together, these two studies provide evidence for a paracrine mechanism of Notch signaling
whereby Notch ligands, previously thought to exist only as transmembrane proteins are packaged into
exosomes and secreted into the extracellular space. In both cases the exosomal Notch ligands were taken up
by or bound to recipient cells where they were shown to affect the expression of downstream Notch targets.
Physiologically relevant effects following exosome treatment were also demonstrated, predominantly with
respect to angiogenesis. While these studies do not directly address cell types found within the CNS, they do
describe proteins and signal transduction mechanisms that are very relevant to the CNS. Given the
requirement for tight control over Notch signaling for CNS development, and the fact that until recently it
was believed that Notch signaling was possible only in instances of cell-cell contact, these findings raise
important and interesting questions regarding the potential implications of paracrine Notch signaling within
the CNS. Furthermore, these findings implicate exosomes as potentially useful vehicles to modify Notch
signaling. A remarkable variety of cargo, including transmembrane proteins (e.g. Notch ligands) are
packaged into exosomes and it is likely that further studies may uncover additional Notch ligands or other
effectors of Notch signaling within exosomes.
Given the breadth of knowledge concerning demonstrable signal transduction via exosome secretion, the
relevance of Notch signaling to NSC/astrocyte cell biology, and the identification of Notch signaling
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elements within secreted exosomes, we hypothesized that exosome secretion may act as a mechanism of
paracrine signal transduction in astrocytes. Furthermore, we hypothesized that Notch signaling elements may
be implicated in this mechanism of signal transduction. To test these hypotheses, we designed and carried
out a number of experiments to isolate exosomes from cultured astrocytes and probe their protein content,
and potential relationship to the Notch 1 receptor and Notch signaling.
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Materials and Methods
Cell Culture
NSC: The isolation and culture of Rad-NSCs has been described previously 57. In brief, mice were subjected
to a permanent distal middle cerebral artery occlusion (dMCAO) as previously described and NSCs were
isolated from the peri-infarct area of the brain following three days of recovery. Following isolation, cells
were cultured in T-75 flasks with NSC-Full medium consisting of Neurobasal-A Medium (Gibco)
supplemented with 1x B27, 100 U/mL penicillin, 100 ug/mL streptomycin, 2mM L-glutamine, 20 ng/mL
bFGF, 10 ng/mL EGF, and 5 ng/mL Heparin Sodium Salt. Upon reaching confluence, cells were passaged
enzymatically by 1x PBS wash and lifted with 0.25% Trypsin. The cell suspension was spun at 500 x g for 5
minutes and the cell pellet was resuspended in fresh NSC-Full medium for subculture.
Astrocyte: Differentiation of astrocytes from NSCs was achieved by addition of DMEM:F12 medium
containing 10% FBS, 100 U/mL penicillin, and 100 ug/mL streptomycin (hereafter referred to as DMEM:F12
unless otherwise specified) for seven days. Medium was changed every three days. To induce knockdown in
cells isolated from animals harboring GFAP-Cre Notch 1-flox cassettes, 1 mM 4-OH tamoxifen (Sigma
Aldrich) or equivalent volume 100% ethanol (vehicle) was added to the medium for ten days after
differentiation was completed.
Cells were counted using a manual hemocytometer prior to plating for all experiments. 1.5 million cells were
plated per 60 cm2 culture surface (equivalent to a 10 cm dish). For differentiation, NSCs were plated in
culture vessels previously coated with 5 ug/mL Poly-d-Lysine/Laminin (PDL, Corning). For
immunofluorescence experiments, glass coverslips were added to the culture vessels and coated with PDL.
In these cases, 25% more cells were seeded to accommodate for an observed reduction in adherence when
plating onto glass.
Cell Lines: U87 cells were a generous gift from Dr. Diane Jaworski, University of Vermont. These cells
were cultured in DMEM:F12 and passaged enzymatically as previously described.
Immunocytochemistry: Cells were fixed with 4% paraformaldehyde (Electron Microscopy Sciences) for
15 minutes at room temperature and washed 3 times for 5 minutes each with PBS. Fixed cells were blocked
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for one hour at room temperature in immunocytochemistry (ICC )blocking buffer consisting of 5% goat
serum (v/v) and 0.1% Triton X-100 (v/v) (Fisher Scientific) in PBS. Primary antibodies were diluted in ICC
blocking buffer and applied simultaneously overnight at 4°C. Cells were washed three times with PBS.
Secondary antibodies (Molecular Probes) were diluted to 1:1000 in ICC blocking buffer and applied for one
hour at room temperature. A small drop of DAPI fluoromount (Southern Biotech) was applied to the coverslip
before it was sealed onto a glass slide (Fisher Scientific). All imaging was performed on a Leica DM600B
epifluorescent deconvolution microscope.
To count cells for the Gpc4 differentiation experiment, 10 images per condition were taken at
randomly selected, nonoverlapping fields of view. Exposure and gain settings remained consistent between
slides and between conditions. Images were blinded by a third party who retained the blinded image identities
until after counting was completed. Images were imported into ImageJ, and the Cell Counter plugin (NIH)
was used to count total nuclei and Gpc4 puncti-expressing nuclei for each image. Counts were expressed as
ratios and imported into Graphpad Prism for analysis.
Cell Lysis and Protein Quantification: Cultures were placed on ice, washed 1x with PBS, and lysed in
RIPA buffer (150 mM NaCl, 1% Triton X-100 (v/v), 0.5% Sodium Deoxycholate (w/v), 0.1% SDS (w/v),
25 mM pH 7.4 Tris) with freshly added protease inhibitor cocktail (Pierce) by manual scraping. 100uL of
RIPA buffer was used per million cells. Lysates were triturated at least ten times with a 27G needle attached
to a 1 mL syringe (BD Biosciences) and incubated on ice for ten minutes. Lysates were then centrifuged at
10,000 x g for ten minutes, the supernatant was transferred to a fresh tube, and then used immediately or
stored at -80°C until use.
Protein concentrations were determined by Bio-Rad DC Protein Assay according to the manufacturer’s
instructions. Absorbance values were read using a BioTek Synergy HT microplate reader at 750 nM.
Western Blotting: 15 uG of cell lysate was combined with 5x Laemlli loading buffer to a final volume of
20 uL, boiled for ten minutes, and briefly centrifuged to collect residual volume. For exosome samples, 10
uL of isolate was combined with 5 uL each of 2x RIPA buffer and Laemlli loading buffer. Samples were
sonicated with three 5 second pulses, then subsequently boiled for 10 minutes and briefly spun in a
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microcentrifuge. Lysates were loaded onto 4-12% gradient, 10 well, 1 mM tris-glycine gels (Invitrogen).
Gels were run at 150 V for 15 minutes, and then at 200 V for one hour.
Gels were transferred onto Immobilon-P PVDF membrane (EMD Millipore) for one hour at 25V
using a Novex XCell II Blot Module (Invitrogen). Transferred membranes were blocked in 5% milk for one
hour at room temperature. Primary antibodies were diluted in milk, typically at 1:1000 or 1:500, and applied
overnight at 4°C. Blots were washed three times for five minutes with 0.2% TBS-T and secondary antibodies
were diluted in milk to 1:2000 and applied for one hour at room temperature. Blots were washed again, and
Pierce ECL Western Blotting Substrate was applied according to the manufacturer’s instructions. Blots were
exposed onto Carestream Biomax film (Sigma Aldrich). Films were scanned at high DPI and quantitated
using ImageJ (NIH) where applicable. Unless otherwise indicated, blots were normalized to ß-actin levels.
Microarray Analysis: RNA was harvested from differentiated astrocytes using a Zymo Research QuickRNA Miniprep Kit. RNA was processed for quality control and microarray by the University of Vermont
Integrative Genomics Resource Core (VIGR). A GeneChip Mouse Gene 2.0 ST Array (Applied Biosystems)
was used for microarray analysis. Downstream bioinformatics assessment was also performed by the VIGR.
Exosome Isolation: Exosomes were isolated from astrocytes by differential ultracentrifugation. Cultures
were washed three times with PBS to remove contaminating FBS, Astrocyte Defined Medium (ADM)
consisting of a 1:1 mixture of Neurobasal-A : DMEM:F12 supplemented with 1x B27, 100 U/mL penicillin,
100 ug/mL streptomycin, 1% L-Glutamine, and 5 nG/mL heparin-binding EGF was added, and the medium
was left to condition for three days. Medium was harvested by aspiration and kept on ice.
All subsequent centrifugation was performed at 4°C. The medium was first spun at 2000 x g for 30
minutes to pellet dead cells. The supernatant was transferred to a fresh tube and spun at 10,000 x g for 45
minutes to remove contaminating vesicles and smaller debris. Finally, the supernatant was passed through a
0.2 uM syringe filter. Precleared medium was subjected to differential ultracentrifugation in a Beckman
Coulter Optima L-90K centrifuge with a 90 ti fixed angle rotor. Medium was first spun at 100,000 x g for 70
minutes. The supernatant was discarded, and pellets were resuspended in 1 mL PBS and combined. An excess
of PBS was added, and the suspension was spun at 100,000 x g for 60 minutes. The resulting pellet was
resuspended in sterile PBS (100 uL per 200 mL starting media volume) and stored at -80°C until use.

18

Exosomes were also isolated using magnetic activated cell sorting. For MACS-based exosome
isolation, an anti-CD9 Exosome Isolation Kit (Miltenyi Biotech) was employed and used according to the
manufacturer’s instructions. Cell culture medium used for MACS isolation was precleared in the same
manner as for UC.
Isolation of exosomes from mouse brain cortex was accomplished using the MACS approach.
Cortices were microdissected in Neurobasal-A medium warmed to 37°C and transferred into an enzyme
solution consisting of 200 U papain (Worthington), 20 μg/mL DNase (Worthington), 1.5 mM EDTA (Fisher
Scientific), 1.5 mM CaCl2 (Sigma), 2 mg L-cysteine (Sigma), and DMEM:F12 (no serum) for 15 minutes.
Tissue was transferred to a stop solution of DMEM:F12 (no serum) with 15 mG trypsin inhibitor (Invitrogen)
and 15 mg BSA (Fisher) and triturated thoroughly. The preclearing procedure previously described for
exosome isolation was followed for tissue samples.
Isolation of Peripheral Blood Plasma: Five mL of whole blood was collected into sodium citrate vacutainer
tubes (BD Biosciences) by a staff phlebotomist and mixed by inversion. Whole blood samples were combined
and spun at 1000 x g for 15 minutes at 4°c then at 2000 x g for 10 minutes at 4°c to remove cells and platelets,
respectively. The resulting plasma samples were collected and subjected to the previously described
preclearing procedure. Exosomes were isolated from precleared plasma samples by anti-CD9 MACS as
previously described. All procedures involving human donors were performed in accordance with and after
approval by the institutional IRB (protocol # 19-0169).
Nanoparticle Tracking Analysis: Nanoparticle tracking analysis was performed on ultracentrifuge-isolated
samples using a Zetaview Twin Particle Tracking Analyzer. The instrument was calibrated prior to use with
a 1:250,000 dilution of the manufacturer provided polystyrene bead standard. Equivalent volumes of
ultracentrifuged exosome isolates were diluted into 5 mL of autoclaved Millipore water and mixed by gentle
inversion. One milliliter of diluted sample was injected into the instrument per run.
Proliferation Assay: To assess changes in cell proliferation after exosome treatment, equal numbers of NSCs
were seeded in 6-well plates. Two hours after seeding, cells were treated with 25 uL of MACS exosome
suspension or a vehicle control. Cells were allowed to grow for 48 h, at which point the cells were processed
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with a CyQuant Cell Proliferation Assay according to the manufacturer’s instructions. Microplates were read
on a BioTek Synergy HT microplate reader.
RT-PCR: RNA was isolated from vehicle or exosome-treated astrocytes using a Zymo Research Quick-RNA
Miniprep Kit according to manufacturer instructions. RNA eluents were subsequently processed using
TURBO DNase (Invitrogen) treatment to remove residual genomic DNA contamination, as per the
manufacturer’s instructions. The concentration of the final RNA eluent was determined using a NanoDrop
spectrophotometer and immediately prepared for a reverse transcription reaction. Reverse transcription was
performed using Superscript IV Reverse Transcriptase (ThermoFisher) with 1.5 uG input RNA. PCR
reactions were performed with OneTaq DNA polymerase (New England Biolabs) and PCR products were
analyzed by agarose gel electrophoresis (1.5% agarose gel, 70V). Gels were imaged on BioRad Chemidoc
imager.
Recombinant Jagged-1 Production: Rat Jagged-1 with a terminal FC tag was expressed in HEK293 cells.
Cells were grown to 85% confluence in 150 mm dishes in DMEM:F12. Once cells were confluent the
medium was changed to serum-free DMEM:F12 and conditioned for two days. After 2 days the medium was
harvested and cell viability was assessed; in most cases it was possible to replace with fresh serum-free
medium and condition for another two days. If viability was noticeably poor, or cells were too dense, they
were discarded. Medium was stored at -20°C and culture was continued until a minimum of 2 L had been
harvested.
Ammonium sulfate was added to the full volume of harvested medium to a concentration of 1.7 M under
gentle heat and stirring. Once fully dissolved, the entire mixture was passed through a 0.2 uM vacuum filter.
The precipitated Jagged-1 was trapped by the filter and eluted into a sterile container with 10 mL PBS per 2
L starting volume. The eluent was dialyzed overnight at 4°C in at least 4 L of PBS using 12,000-14,000
MWCO dialysis tubing (Fisher). The excess PBS was replaced the following morning and dialysis continued
for 6 hours. The dialyzed solution was concentrated Amicon Ultra Centrifuge Filter concentrators with a 3K
cutoff to approximately 1 mL per 10 mL initial resuspension volume and stored at -80°C until use. Jagged-1
concentration was determined by R&D Duoset ELISA, according to instructions, which was read on a BioTek
Synergy HT microplate reader.
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Results
To investigate the potential role of exosomes in paracrine signaling in the CNS, we isolated exosomes from
ex vivo differentiated mouse astrocytes. Two methods of isolation were employed: the widely utilized
method of differential ultracentrifugation (UC) and MACS. The MACS approach, often employed for cell
isolation from tissues, utilizes a ferromagnetic microbead conjugated to a specific capture antibody. In our
case, anti-CD9 MACS beads were employed, as the tetraspanin protein CD9 is highly enriched in exosomal
membranes. MACS isolation is in many cases a preferable methodology in comparison to UC, given the
antigen-specificity of the MACS isolation and the comparably small required input for efficient isolation (a
minimum of 50 mL for UC vs. 2 mL for MACS).
In both cases, samples were processed for SDS-PAGE immunoblotting to verify the successful
isolation of exosomes. After 3 days of conditioning with serum-free ADM (to avoid detection of exosomes
present in residual serum), astrocyte exosomes were readily detected in isolates prepared by UC or MACS
(Figure 1). Positive identification of exosomes was achieved via probing for the presence of CD81, another
tetraspanin that is highly enriched in exosomes. Curiously, MACS exosome samples displayed a second,
higher molecular weight band when probed for CD81; though consistently observed in MACS samples this
band was not present in UC samples, and its identity could not be determined in the course of these
experiments (Figure 1). Under an IRB-approved protocol (# 19-0169), exosomes were successfully isolated
from four separate samples of human donor blood plasma as well as from mouse cortical tissue (by MACS)
(Figure 1). The CD81 band resulting from mouse cortical tissue ran at a slightly higher molecular weight
than that of cultured astrocyte samples. This phenomenon was not explained in our experiments but could be
the result of CD81 isolation from multiple cell types or from the retention of CD81 binding partners in the in
vivo environment.
Nanoparticle tracking analysis (NTA) was conducted on UC-isolated exosome samples to probe
their relative concentrations and particle size distributions. NTA was conducted to ensure the particles in UC
isolates are indeed exosomes, based on their physical properties. Equivalent volumes of Notch 1 control and
knockout-derived exosomes, as well as exosomes isolated from donor cells stimulated with the Notch ligand
Jagged 1, were subjected to NTA. Average peak particle size was within the range established for exosomes
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for all samples, although a comparably small amount of contaminating larger particles were also present.
Small differences in particle counts between treatments were present at most if not all particle size ranges.
Most striking, however, was the significant increase in concentration observed in the ADEs isolated from
cells pretreated with Jagged 1 (Figure 2).
Immunoblotting was subsequently conducted to examine the protein cargo of astrocyte-derived
exosomes (ADEs). Several Notch 1 related targets were probed, given the relevance of Notch signaling to
NSC/astrocyte biology. While Jagged 1 was not detected in ADEs, NICD was reliably and robustly detected
in exosome samples (Figure 3). The astrocytes used in our study harbored a GFAP-creERTM Notch 1-/cassette. In cultures of primary adult astrocytes, Notch 1 was deleted by addition of 1 uM 4-OH tamoxifen
to the culture medium. In experiments with 4-OH tamoxifen treatment, significantly decreased levels of
NICD were observed in isolated exosomes as compared to cells treated with an ethanol vehicle control
(Figure 3).
To assess the ability of exosomal NICD (exNICD) to affect recipient cells, we attempted to
determine if exNICD could affect NSC proliferation. Equivalent numbers of NSCs were seeded into 6-well
dishes and treated with normal or Notch 1 knockout MACS exosomes along with the microbead vehicle
control. After 3 days of growth, cell proliferation was assessed using a CyQuant Cell Proliferation assay. No
observable differences in proliferation resulted from treatment with either normal or Notch 1 knockdown
exosomes (Figure 4). Given that CD81 expression may be regulated, in part, by Notch 1, the effect of
exosome treatment on CD81 was examined by immunoblotting. No significant differences in CD81
expression were observed after exosome treatment (Figure 4). While these data certainly do not preclude the
possibility that exNICD exerts a biologically relevant effect in recipient cells, it could not be demonstrated
herein.
A microarray analysis was performed to compare gene expression in control and Notch 1
knockdown astrocytes (Table 2). Glypican 4 (Gpc4) was identified amongst the many genes that were
differentially regulated in response to Notch 1 knockdown, being expressed at an approximately 2-fold lower
level in Notch 1 knockout cells as compared to control cells (Figure 5). Gpc4 is a heparan sulfate proteoglycan
that has previously been studied as an astrocyte paracrine factor involved in the organization of neuronal
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synaptic receptors58. Further confirmation of Notch involvement in Gpc4 regulation came in the form of the
identification of Notch consensus binding sites within the Gpc4 promoter/enhancer regions (Figure 5).
Subsequently, staining experiments were performed in U87 glioma cells and differentiated astrocytes to
observe the distribution of Gpc4 expression. Surprisingly, significant Gpc4 expression was observed within
the nucleus in both cell types, but more so in astrocytes (Figure 6). Gpc4 is often reported as a membranetethered58 and a secreted protein59, nuclear Gpc4 has previously been reported in neuronal and glial cells60.
While it remains possible that the observed Gpc4 staining is peri-nuclear, rather than truly nuclear in origin,
preliminary immunoblotting experiments have identified Gpc4 as present within the nuclear fraction of
astrocyte whole-cell lysates (data not shown), supporting the localization of this staining pattern to the
astrocyte nuclei.
We hypothesized that the function of nuclear Gpc4 might be related to cell division or proliferation.
To test this hypothesis, the localization of Gpc4 in early-stage differentiating NPCs was compared to that of
fully-differentiated RAD-NSC derived astrocytes. No consistent correlation between punctate nuclear Gpc4
and differentiation status could be established (Figure 6). Two donor cell lines were tested in this
differentiation paradigm and, interestingly, these donor lines displayed an inverse pattern of nuclear Gpc4
staining; in one line, nuclear puncti were predominantly present at the 14 day timepoint, whereas in the other
donor line a majority of nuclear puncti were observed at the 3 day timepoint (Figure 6).
An alternative hypothesis regarding the function of nuclear Gpc4 was also explored. The pattern of
staining displayed by Gpc4 in the astrocyte nucleus strongly resembled that of factors involved in the
regulation of alternative splicing. As such, staining experiments were performed to colocalize Gpc4 with
relevant proteins known to be involved in the regulation of splicing or other mechanisms governing gene
expression. Gpc4 failed to colocalize with 5-methylcytosine, a marker for the associated epigenetic regulator
Tet3 (data not shown). It did, however, colocalize to some extent with splicing regulator RbFox3 (Figure 6).
Given the known role of RbFox3 in the regulation of alternative splicing, these data suggest that Gpc4 may
function in or be a target of alternative splicing.
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Discussion
Recent expansion and diversification in the field of exosome research has provided valuable knowledge but
has also raised many questions about the role that exosomes play in cell biology. While many individual lines
of evidence suggest important roles for exosomes in a variety of cellular processes, we still lack a complete
understanding of the core mechanisms that regulate key aspects of exosome biogenesis, cargo loading,
secretion, and target cell selection. These questions are becoming more important as we begin to realize the
role exosomes play as vehicles for cell signaling.
We have described a complete and scalable procedure for the isolation of exosomes from ex vivo
differentiated astrocytes. Importantly, our culture and pre-clearing procedures are compatible with two
commonly utilized methodologies for the isolation of exosomes; ultracentrifugation and immunocapturebased MACS isolation. The procedure can thus be altered according to the desired outcome and intended
application for the isolated exosomes; UC can be employed to isolate large volumes of exosomes from
accordingly large volumes of culture medium, whereas MACS can be employed for antigen-specific and
rapid isolation of exosomes from smaller volumes of culture medium that would be prohibitive to efficient
UC isolation.
To our knowledge, we report for the first time the detection of NICD within ADEs. This is
significant given that NICD has powerful effects on cell proliferation and differentiation. Our observation is
distinct from previous reports of exosomal Notch signaling44, 45, which describe the incorporation of Notch
ligands, but not Notch receptor elements, into exosomes. This aspect is of particular interest because Notch
receptor ligands can be either agonistic or antagonistic as signals, whereas cleaved NICD is inherently
agonistic to Notch signaling. For example, one of the reported cases involving an exosomal Notch ligand
concerns exosomal transmission of Dll4, an inhibitory Notch ligand 44.
Several potential factors could have contributed to the lack of response to exNICD observed in our
experiments. Methodological issues could have precluded a measurable response to ADE treatment. All
treatment experiments were performed using samples isolated by MACS, and samples isolated in this manner
retain the antibody-ferromagnetic bead complex used for isolation. Given that our MACS approach targeted
CD9, and the fact that tetraspanin protein expression patterns are thought to be one mechanism regulating
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the target selection and uptake of exosomes14, it is possible that the retained microbead complex disrupted a
protein-protein interaction necessary for exosome binding or uptake. Another possible explanation is that the
NICD contained with ADEs is somehow post-translationally modified so as to be incapable of binding to the
nuclear cofactors necessary for its typical regulatory activity. While our experiments failed to demonstrate a
cellular response to ADE-NICD, they were by no means comprehensive. Accordingly, it is possible that
ADE-NICD is biologically active in a context we did not investigate.
Glypican 4 was also identified as a putative Notch-regulated factor with potentially significant
implications for astrocyte cell biology and signaling. Using a loss-of-function approach, we have identified
Gpc4 as regulated by Notch signaling; this was a novel observation. Gpc4 was previously investigated with
respect to its activity as a paracrine factor59, but the work described herein suggests a role for the protein in
cell-autonomous activity in astrocytes.
Gpc4 and related heperan-sulfate proteoglycans (HSPGs) are described as membrane-tethered or
secreted. In contrast to these reports, we observed significant nuclear expression of Gpc4 in differentiated
astrocytes. While this pattern of expression was consistently observed, it did not appear to correlate with
differentiation in a consistent manner. Further staining experiments revealed that nuclear Gpc4 colocalizes
with RbFox3, an important regulator of alternative splicing in the CNS. It is possible that Gpc4 regulates
differentiation, albeit via a non-direct mechanism, given the functions of RbFox3 in the regulation of
differentiation61, 62. The potential interaction between RbFox3 and Gpc4 is particularly interesting given the
role of secreted Gpc4 in the regulation of excitatory synaptogenesis and synaptic organization58. Future
experiments interrogating the possible alternative splicing of Gpc4, its specific role within the nucleus, and
the potential contribution of astrocytic Gpc4 to neuronal differentiation should be conducted.
The work described herein presents a variety of opportunities for further experimentation. The most
pressing question raised by this body of work concerns the function of exNICD; its presence within astrocytesecreted exosomes has been repeatedly demonstrated, however the function of the protein or the reason for
its incorporation into exosomes has yet to be determined. In parallel to the major hypotheses regarding the
functions of exosomes more generally, two possibilities exist with respect to exNICD: 1. that exosomes are
used to remove excess or deficient NICD from the cell as waste, or 2. that exosomal NICD is a vehicle for
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cell signaling with consequences that were not identified within the described experiments. The answer to
this question will ultimately describe either a cell autonomous or a non-cell- autonomous role for exNICD,
with significant implications for CNS development and glial cell signaling.
Several experiments could be designed to assess whether NICD accumulates within the exosome as
a waste product. Most basically, levels of exNICD could be assessed in the presence or absence of lysosome
inhibitors, such as leupeptin or bafilomycin A. If NICD does accumulate within exosomes as a means of
waste disposal, it would be logical to assume that inhibition of the other endosomal waste disposal pathway
would upregulate NICD trafficking to the exosome. It would also be of value to profile exNICD by mass
spectrometry and to compare it to NICD from cells in its normal context, an experiment that was attempted
as part of this project but failed to detect significant protein constituents within exosomal isolates (likely due
to methodological issues). It is possible that NICD, prior to or as a part of its incorporation into exosomes, is
post-translationally modified or cleaved in a manner rendering it inactive or incapable of signaling. Such
modifications have been described63 and would suggest that exNICD is not intended as a signaling molecule
but is in fact a waste product. Lastly, it could be informative to examine the consequences of inhibition of
exosomal biogenesis/secretion on intracellular Notch dynamics. This inhibition can be accomplished
pharmacologically, via treatment with the compound GW4869. If exosomal NICD is post-translationally
modified as a waste product, inhibiting exosome secretion in this manner may have little observable effect
on cell-autonomous Notch signaling. If exosomal NICD is signaling-competent, however, it is possible that
inhibiting exosome secretion in this manner would result in aberrantly high Notch signaling or Notch target
gene expression within the cell, thus informing our understanding of the role of exNICD.
Several experiments could similarly be conducted to specifically assess whether exNICD acts as a
non-cell autonomous signaling molecule. It would first be important to definitively establish that ADEs are
in fact internalized by recipient cells. This could be accomplished by lipophilic dye staining of isolated
exosomes, or by overexpressing GFP under the control of a tetraspanin protein promoter (in the course of the
described experiments, a U87 cell line expressing CD63-EGFP was engineered, but fluorescence was poorly
expressed even in whole cells, and while GFP protein was detected in exosome samples by immunoblot,
fluorescence was not detectable by microscopy). Once exosome uptake is established, comprehensive qPCR
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screening could be conducted to examine Hes and Hey gene expression following treatment of cultured cells
with NICD containing exosomes. Given the putative importance of tetraspanin expression for exosome
uptake, and the fact that tetraspanin epitopes may be masked by antibody/microbead binding in MACS
isolations, it would be important to carry out these treatments with exosomes isolated by UC or alternatively
dissociate the conjugated microbeads from exosome samples isolated by MACS.
In preliminary experiments, addition of exosomes to cultured NSCs did not predispose them to
differentiate in the absence of any additional stimulus. In this assay, exosomes were added to NSCs cultured
under normal maintenance conditions, and differentiation was assessed after 1 week by staining for neuronal
(ß3-tubulin), astrocyte (GFAP), and NSC (nestin) markers. Similar but more comprehensive experiments
could be conducted in this manner to examine whether exNICD could, by affecting Notch-related gene
expression, prevent differentiation in the presence of otherwise pro-differentiating conditions. As described
in one of the publications detailing their initial isolation, RAD-NSCs can be induced to differentiate into
neurons by the addition of dbcAMP and FGF64. Assessing neuronal differentiation in the presence of these
factors, with and without the addition of NICD-containing exosomes, would provide valuable information
on the capacity of these exosomes to leverage control over differentiation in the CNS while also
demonstrating the physiological and biological relevance of exNICD. A similar experiment could be
conducted with respect to NSC differentiation into astrocytes, which can be induced simply by addition of
10% FBS into the culture medium. Taken together, these experiments would likely provide a convincing
identification of the role of astrocyte exNICD, as either a means of waste disposal or as a vehicle for cell
signaling.
The experiments performed herein with respect to the expression of Gpc4 in astrocytes also provide
a significant basis for further experimentation. Most fundamentally, additional experiments should be
conducted to definitively localize protein expression to the nucleus in astrocytes. Preliminary
immunoblotting experiments have identified the protein as present with the nuclear fraction of the whole cell
lysate, experiments which can easily be repeated and refined with a more specific Gpc4 antibody.
Experiments precluding the possibility of colocalization with peri-nuclear markers (of the endoplasmic
reticulum, mitochondria, etc.) should also be conducted. Finally, additional staining experiments could
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subsequently be conducted to colocalize Gpc4 expression with additional proteins involved in alternative
splicing to more robustly establish the putative relationship of Gpc4 with alternative splicing, as was
preliminarily demonstrated with RbFox3.
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Figures

Figure i. Diagram of the mechanisms involved in exosome
biogenesis.
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Figure 2. Nanoparticle Tracking Analysis of Astrocyte-Derived
Exosomes. A. Overall size distribution of ADEs isolated from
control, Notch1 knockdown, and Jagged 1-stimulated
astrocytes. B. Relative concentrations of particles within the
exosome range. C. Relative particle sizes displayed as a
percentage of total measured particles. D. Relative particle size
percentages of 400nm+ low-abundance particles.
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Figure 5. Notch1 regulates Glypican 4 (Gpc4). A. Differential
expression of Gpc4 in astrocytes in response to Notch1 knockdown.
B. Notch/CSL binding sites located within promoter and enhancer
regions. C. Process and Pathway enrichment in response to Notch1
knockdown of Gpc4.
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Figure 5. Notch1 regulates Glypican 4 (Gpc4). A. Differential
expression of Gpc4 in astrocytes in response to Notch1 knockdown.
B. Notch/CSL binding sites located within promoter and enhancer
regions. C. Process and Pathway enrichment in response to Notch1
knockdown of Gpc4.
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Antibody

Source

α-CD81 (WB 1:500)

Santa Cruz (sc-166028)

α-NICD (WB 1:1000)

Abcam (ab8925)

α-Glypican 4 (WB, ICC, IHC 1:500)

ThermoFisher (PA5-72360)

α-ß Actin (WB 1:1000)

Millipore Sigma (A5316)

α-Rbfox3 (ICC 1:500)

Cell Signaling Technologies (94403)

α-Jagged 1 (WB 1:1000)

Cell Signaling Technologies (70109)

α-5-methylcytosine (ICC 1:500)

Eurogentec (BI-MECY)

α-GFAP (ICC+IHC 1:500)

Millipore Sigma (G9269)

Alexafluor α-mouse 488 (1:1000)

Molecular Probes (A-11029)

Alexafluor α-rabbit 488 (1:1000)

Molecular Probes (A-11008)

Alexafluor α-mouse 594 (1:1000)

Molecular Probes (A-11005)

Alexafluor α-rabbit 594 (1:1000)

Molecular Probes (A-11012)

Alexafluor α-rat 488 (1:1000)

Molecular Probes (A-11006)

Table 1. Antibodies Used and Sources
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Gene

Fold Change Relative to
Control

Upregulated
Renbp

12.35

Brinp3

6.15

Zdhhc2

3.78

Hist3h2ba

3.10

Kirrel3

2.89

Thy1

2.88

Cd200

2.83

Eya1

2.74

Akap12

2.73

Gpc4

2.11

Downregulated
Slc38a1

-19.31

S100a6

-14.95

Tppp3

-14.41

Cxcl10

-12.45

Timp1

-11.64

Saa3

-11.58

Ccl5

-11.42

Ccl2

-9.59

Nrn1

-9.05

Ccl7

-8.52

Table 2. Major Genes Identified as Differentially Regulated After Notch 1 Deletion
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Appendix A: IRB Approved Protocol Related to Collection of Blood from Human Donors
f
The University of Vermont Committees On Human Research

Blood Collection Protocol for Non-Clinical Laboratory Research

This form is to be used when the only procedure involving human subjects is blood collection. If
any other procedures are being included STOP and complete the Common Protocol Cover form
and submit a written protocol. See forms page for forms and instructions.

1. Title of this Blood Collection Protocol
Isolation of CNS-Derived Exosomes from Human Peripheral Blood Plasma
Protocol(s) in which this blood will be used
(this could be a human subjects (IRB), animal (IACUC) or biosafety (IBC) protocol)

2.

Committee

Number

Protocol Title

Committee

Number

Protocol Title

Committee

Number

Protocol Title

Investigator Information
Principal Investigator (PI):
Dept.

Medicine

Campus/Office Address:

Jeffrey Spees
Phone

802—656-2388

Degree

Ph.D.

Email

Jeffrey.spees@med.uvm.e
du

Colchester Research Facility Rm. 159

PI’s Dept. Chair(s)

Do you want to appoint a primary contact other than the PI?

Yes

No

x

Investigators wishing to appoint a contact for all IRB communications should complete the contact information
requested below. Primary contacts are considered “key personnel” and must complete required human
subjects training.
Contact Full Name

Email

Department /Address

Phone

ii

3. Purpose of Blood Collection
Small (10-15mL) volumes of blood will be collected from healthy human subjects of both sexes. Samples will be deidentified from donating individuals immediately post-collection and referenced only by arbitrary identifying
numbers. Some identifying information such as sex and age may be retained. This minimal-risk procedure will be
the only part of this expedited IRB protocol directly involving human subjects. Blood samples will be centrifuged to
separate plasma from whole blood, and plasma samples will be subjected to a magnetic sorting protocol to isolate
small protein-containing vesicles called exosomes. Exosomes will be sorted based on epitopes specific to brainderived cells. We will analyze these exosomes based on a variety of metrics, principally including protein content
differences between individuals of different age or sex. The vast majority of the work conducted under the purview
of this IRB will be standard bench science, with the collection of small blood volume being the only use of human
subjects for research.

4. Committee Review Type
The type of review depends upon the amount of blood you are collecting over what time period. Check below
the intended collection requirements.
x

Expedited Review Required
Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows: (a) from
healthy, non-pregnant adults who weigh at least 110 pounds as long as the amounts drawn will not
exceed 550 ml in an 8 week period and collection will not occur more frequently than 2 times per week.
Full Board Review Required
Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows: (a) from
healthy, non-pregnant adults who weigh at least 110 pounds as long as the amounts drawn will exceed
550 ml in an 8 week period and collection will occur more frequently than 2 times per week.

5.

Source of Support
Is there any external funding for this project?

Yes

x No

If “Yes” and there is a SPA Proposal provide the InfoEd #

6.

Funding via Department of
Medicine.

Donor Information
a. Donor Demographics
Estimate the Total Number of Donors Required

10-15

Type of Donors (check all that apply):
This form cannot be used for research with minors, vulnerable subjects, immunocompromised subjects, or
persons with specific disorders.
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x

Male

x Female

Age Range

x

*Students or Employees or Colleagues

21-60

(must be >18 yo)

*If donors are employees, colleagues, or students explain how undue influence will be avoided.
Blood donation must always be voluntary. These donors should not be placed under pressure to give
samples. All potential donors should be able to refuse to give blood, without having to give an explanation
for a refusal. Any personal information obtained in connection with collection or use of a sample must be
held in confidence.
No pressure will be exerted on any colleague or student to donate blood to this study. There are ample
potential donors and only a small number of donors will be required for our study, so no individual donor is
under any undue pressure to donate and the refusal to donate by any individual participant will be
ultimately inconsequential to our study. Additionally, a graduate student will be the primary individual
soliciting donation, so no superior to employee dynamics will be at play.
b. Donor Selection:
Provide rationale, if any, for specific donor selection in terms of the scientific objectives of the protocol(s) in
which the blood will be used. (e.g. gender, weight, etc)
We will attempt to obtain samples from both male and female donors. We will also attempt to obtain donations
from individuals of differing age. No other selection criteria will be employed.
c. Donor Compensation
Will donor be compensated?

x

If yes, amount per donation

$10

Yes

No
Total Amount

$150

For all UVM studies, the Payment Acknowledgement form is required to reimburse subjects. If not using this
form, explain how you will be obtaining the subjects’ social security number for payment purposes (e.g., on
paper, verbally). UVMMC does not require this form to be used, however it does require social security
numbers regardless of amount. (The UVM payment threshold for collecting a person’s social security
number is equal to or less than $100.00 while UVMMC requires subject social security numbers regardless
of amount. Seek additional guidance from UVM’s Procurement Services Office or UVM Medical Center’s
Accounts Payable Department.)
Explain how you will collect name and contact information, and if applicable, the social security number.
How will you protect this information?
Names and contact information will be collected with the study informed consent form prior to sample
collection. This information will be kept secure as it will be stored along with the other confidential medical
information who’s security protocols are detailed elsewhere in this application.
7. Recruitment
Describe plans for identifying and recruiting donors. All recruitment materials (flyers, ads, letters, etc) need to be
IRB approved prior to use.
Donors recruited will largely be colleagues and coworkers of the investigators, and will be personally recruited.
No recruitment materials will be created or distributed.
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8. Consent Procedures
Describe the consent procedures to be followed, including the circumstances under which consent will be
obtained, who will seek it, and the methods of documenting consent.
Note: We would recommend that our consent template developed specifically for this situation be used. It can be
found on the forms page of our website under consent.
A consent form based on the provided template has been developed specifically for this protocol. The form will be
provided immediately after participation solicitation. Once the form has been read, understood, and signed by the
participant they will be brought to the blood draw location. The study key personnel, a graduate student in the
Spees lab, will be the individual soliciting participation as well as obtaining and documenting consent.
9. Procedures for Obtaining Blood
Provide a narrative of the collection procedures.
Example below, please review and revise as necessary for this protocol.

Procedure:
1. Healthy adult individuals will be asked to participate in this minimal risk procedure. Education and
review of the consent will be performed. To avoid the risk of fainting, the person should have eaten
something prior to the draw.
2. After the consent is signed, the volunteer will be brought to a room on the second floor of the
Colchester Research Facility dedicated to venous sampling for research studies.
3. Phlebotomy of a peripheral arm v`ein will be performed by Heidi Taatjes using sterile procedures and
seated position. A sterile bandage will cover the phlebotomy site after the procedure and the arm will
be elevated to ensure that bleeding has stopped.
4. The volunteer will be observed for any lightheadedness, bruising or bleeding during and after the
procedure.
5. If the volunteer is lightheaded, he/she will be reclined and monitored until symptoms resolve.
6. If the volunteer is asymptomatic after the phlebotomy procedure, he/she will be released.
7. Any volunteer with any side effects during or after phlebotomy will not be used again to obtain the
blood products. In addition, any volunteer that requires more than three attempts to access a vein will
also not be used as a volunteer.
10. Donor Risks
a. Explain experience/training of the collector.

Heidi Taatjes was taught to draw blood under the
supervision of Dr. David Schneider, and has
performed phlebotomy on over 100 individuals as
part of multiple studies for the Cardiovascular
Research Institute (CVRI).

See policy on acceptable experience.

b. Will any private information be collected from the individual? Describe what information you need
below and whether you need to keep any of the individual’s answers. (Justification for maintaining
private information will be required. A plan for protecting the information will also be required.)

46

Sex and age will be the only information collected from participants. This information will be stored on a
password-protected computer in the Colchester Research Facility, which is an access-restricted facility open
only to UVM personnel.
c. Will the blood samples be linked with identifiers or codes?
x

Yes

No

If yes, explain why identification is necessary and how the data will be protected.
Identification will be necessary to maintain the relationship between blood sample and donator sex and age.
Data protection will be achieved as per the above description.

e. How, where and for how long will the samples be maintained? (will samples be secure?)
Samples will be processed immediately for isolation of plasma proteins. These protein samples will be
maintained in the secure Colchester Research Facility.
f. Amount and Number of Donations: How many times will donors potentially donate? Over what time
period?
One donation per donor will probably be sufficient. If additional samples are required for replication then
participants may be asked to provide a second donation after a significant period of time has elapsed.
Where blood is to be collected regularly from a donor, a record of donations and the total collected should be
maintained. The total (including donations elsewhere) should not exceed 550ml in an 8 week period. Note:
Hemoglobin measurements may be indicated if the same person is donating very frequently.

f.1. The researcher is required to maintain a blood drawing log. This log should include
1. Date of donation 2. Person’s name
x

3. Amount drawn

Confirm that a log will be maintained by checking here.

f.2. What is the largest sample size to be collected in one sitting?

10mL

g. Where will the collection take place? List all potential sites. See policy regarding Blood Draws Outside
of Clinical Care Areas.
Colchester Research Facility, in a room separate from other research activities
h. Unanticipated Problems with a donor needs to be reported to the Institutional Review Board.
Explain the process for this notification.
Participants will be monitored for 10 minutes subsequent to venipuncture for evidence of any adverse
reaction. Participants will also be provided with contact information for study personnel to whom they can
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report any unanticipated problems. Any such issues will be immediately reported to the IRB as procedure
requires.

11. Collector Risk
a. Has collector had appropriate blood-borne pathogen training? Required per policy.
x

Yes

No

b. Confirm by checking here, that collector(s) have been trained in phlebotomy.

x

I Confirm

c. If the intent is to transform lymphocytes, confirm here that the collector will not be working with
their own blood samples.
I Confirm

x

Not Applicable

No one should work with their own blood samples if the intention is to transform lymphocytes. In the event
of an accidental exposure, their immune system will not challenge the transformed cells.

d. Confirm that the collector will use the following safe Sharps practices.











x

I Confirm

Use a Vacutainer collection equipment whenever feasible
Wear gloves when taking blood
Needles should never be recapped
Never carry used sharps in your hand
Sharps disposal containers should be available at the point of use
Used equipment should be discarded into a sharps disposal container immediately after use
Equipment should never be reused
Sharps containers should never be over-filled: discard when ¾ full
Needles and syringes should be discarded as a single unit
Any inoculation accident from contaminated equipment should be reported as an accident to both the
IRB and IBC and advice sought from UVM’s or UVM Medical Center’s Occupational Health Program
as soon as possible.

e. Confirm that the collector will use BSL-2 Laboratory Safety Practices

x

I Confirm

f. Donors should be asked not to donate if they may be infected with a blood-borne virus
or become a regular donor if they think that they may be at risk of infection from, for example, sexual
partners. The template consent language only lists exclusion criteria relating to infection control
and donor protection. Note: The researcher may need to specify additional exclusion criteria to avoid use
of samples that may confound test results, e.g., the donor taking drug treatment or the donor suffering from
hematological disease.
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g. Unanticipated Problems with the collector needs to be reported to the Institutional Review Board and the
Institutional Biosafety Committee. Explain the process for this notification.
The graduate student conducting this study will be present for all blood draws. Any unanticipated problems
with the collector noticed by the student will be reported to the IRB or IBC as appropriate without delay.

12. PERSONNEL ROSTER
Please complete the “Personnel Roster eForm” through InfoEd. Once all personnel have been added to the
eForm, click "Save & Complete" on the top right of the page. You will be required to complete the eForm when
uploading documents to the new submission.
All key personnel are required to complete online training prior to being added to the protocol. Please do not
include individuals on the roster eForm who have not completed required training. See the CITI Resource Page
for more information and to view tutorial completions.

13. AGREEMENT
PRINCIPAL INVESTIGATOR
As Principal Investigator of this study, I assure the Committees on Human Research that the
following statements are true:
The information that is provided in this form is correct. I will seek and obtain prior written approval from the
IRB for any modifications in the proposal, including changes in procedures, co-investigators, etc. All of the
members of the research team have completed the applicable institutional credentialing processes required
to conduct this research. I will promptly forward any reportable adverse events and unanticipated problems
to subjects or others that may occur in the course of this study. I will not begin my research until I have
received written notification of IRB approval. I will comply with all IRB requests to report on the status of the
study. I will maintain records of this research according to applicable guidelines.

x
Original Signature of PI

Date
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